{"id":"urinary-kallikrein","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Angioedema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Kallikrein activates the kinin-kallikrein system, which generates bradykinin—a short-lived peptide that acts on B1 and B2 receptors to promote vasodilation, increase sodium and water excretion, and reduce vascular resistance. This mechanism helps normalize blood pressure and improve renal hemodynamics, particularly in hypertensive patients. The urinary form is derived from or administered as a biological extract to harness these endogenous regulatory pathways.","oneSentence":"Urinary kallikrein is a serine protease that cleaves kininogen to release bradykinin, a potent vasodilator and natriuretic peptide that lowers blood pressure and improves renal perfusion.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:37:41.684Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Renal protection in hypertensive patients"}]},"trialDetails":[{"nctId":"NCT07483281","phase":"NA","title":"Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Union Hospital","startDate":"2026-05-01","conditions":"Acute Ischemic Stroke","enrollment":220},{"nctId":"NCT07283159","phase":"PHASE2","title":"Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2026-01-20","conditions":"Ischemic Stroke","enrollment":200},{"nctId":"NCT06848894","phase":"NA","title":"Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-03","conditions":"Acute Ischemic Stroke","enrollment":1204},{"nctId":"NCT06211712","phase":"NA","title":"Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-04-17","conditions":"Acute Ischemic Stroke","enrollment":120},{"nctId":"NCT06696703","phase":"NA","title":"Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke (KIF-AIS)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2024-01-01","conditions":"Acute Ischemic Stroke","enrollment":200},{"nctId":"NCT06380699","phase":"PHASE1","title":"Study to Assess PK, Safety and Tolerability in Healthy Subjects","status":"COMPLETED","sponsor":"Changzhou Qianhong Bio-pharma Co., Ltd.","startDate":"2023-03-16","conditions":"Acute Ischemic Stroke","enrollment":56},{"nctId":"NCT06137300","phase":"NA","title":"Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Yi Yang","startDate":"2024-03-15","conditions":"Acute Ischemic Stroke","enrollment":986},{"nctId":"NCT06132880","phase":"NA","title":"Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2023-12-14","conditions":"Acute Ischemic Stroke, Functional Outcomes","enrollment":540},{"nctId":"NCT06085378","phase":"NA","title":"Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2024-01-01","conditions":"Acute Ischemic Stroke, Type 2 Diabetes","enrollment":630},{"nctId":"NCT04102956","phase":"PHASE4","title":"Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients","status":"COMPLETED","sponsor":"The Second Hospital of Hebei Medical University","startDate":"2017-07-01","conditions":"Stroke, Acute","enrollment":80},{"nctId":"NCT04325932","phase":"PHASE4","title":"Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis","status":"WITHDRAWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2016-01","conditions":"Intracranial Arteriosclerosis, Collateral Circulation, Anterior Cerebral Circulation Infarction","enrollment":""},{"nctId":"NCT04020666","phase":"","title":"Effects of Urinary Kallidinogenase in Acute Ischemic Stroke Patients With Abnormal Glucose Metabolism","status":"COMPLETED","sponsor":"The Second Hospital of Hebei Medical University","startDate":"2016-12","conditions":"Acute Ischemic Stroke, Abnormal Glucose Metabolism","enrollment":113},{"nctId":"NCT03431909","phase":"PHASE4","title":"Evaluation Of HUK in Acute Stroke Patients: MRS and CTP","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2014-01-01","conditions":"Acute Ischemic Stroke","enrollment":80},{"nctId":"NCT02562183","phase":"PHASE4","title":"The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein","status":"UNKNOWN","sponsor":"Techpool Bio-Pharma Co., Ltd.","startDate":"2015-08","conditions":"Cerebral Infarction","enrollment":2186},{"nctId":"NCT02806128","phase":"NA","title":"The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship","status":"UNKNOWN","sponsor":"Huisheng Chen","startDate":"2016-11","conditions":"Cerebral Infarction","enrollment":100},{"nctId":"NCT00005261","phase":"","title":"Urinary Kallikrein and Hypertension: A Prospective Study","status":"COMPLETED","sponsor":"University of Utah","startDate":"1990-07","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":""},{"nctId":"NCT02259738","phase":"PHASE2","title":"Multi-modality MRI Study on Effect to Collateral Circulation and Blood Perfusion of Acute Cerebral Infarction by Human Urinary Kallidinogenase","status":"COMPLETED","sponsor":"XuanwuH 2","startDate":"2013-01","conditions":"Cerebral Infarction","enrollment":120},{"nctId":"NCT01558245","phase":"PHASE2","title":"Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis","status":"UNKNOWN","sponsor":"Jinling Hospital, China","startDate":"2011-12","conditions":"Cerebrovascular Disease","enrollment":99},{"nctId":"NCT01250483","phase":"","title":"Effects of Alpha Blockers on Prostate-specific Antigen (PSA) Change in Men With Lower Urinary Tract Symptoms (LUTS)","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2001-01","conditions":"Benign Prostatic Hyperplasia, Prostate Cancer","enrollment":174},{"nctId":"NCT00395005","phase":"","title":"Correlation of Urinary Kallikrein With Cytokines, Proteinuria and Renal Function in Chronic Renal Disease Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2006-10","conditions":"Chronic Kidney Disease","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":957,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Urinary Kallidinogenase"],"phase":"marketed","status":"active","brandName":"Urinary Kallikrein","genericName":"Urinary Kallikrein","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Urinary kallikrein is a serine protease that cleaves kininogen to release bradykinin, a potent vasodilator and natriuretic peptide that lowers blood pressure and improves renal perfusion. Used for Hypertension, Renal protection in hypertensive patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}